Flu drug zanamivir tested against Dengue's deadliest complication

NCT ID NCT04597437

Recruiting now Disease control Sponsor: George Washington University Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This pilot trial tests whether intravenous zanamivir, a drug already used for flu, can reduce vascular permeability — the dangerous blood vessel leakage that is the main cause of death in dengue fever. About 74 people with dengue and warning signs will receive either zanamivir or a placebo for five days. The study will check for side effects and measure biomarkers of blood vessel damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: intravenous zanamivir
What this could lead to: If it works, this could point toward a treatment for the main cause of death in dengue fever.
What could go wrong: This is a small early-stage pilot trial, so results may not be conclusive. The drug is given intravenously, which carries risks like infection or allergic reaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENGUE FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DENGUE FEVER

Contacts and locations

Locations

Cien Salud IPS SAS
ACTIVE_NOT_RECRUITING

Barranquilla, Atlántico, 080020, Colombia
Clinica de la Costa SAS
RECRUITING

Barranquilla, Colombia, 080020, Colombia

More trials for these conditions

Other studies related to the condition(s) this trial covers.